A Comprehensive Nuclear Receptor Network for Breast Cancer Cells

Cell Reports

Volumn 3, Issue 2, 2013, Pages 538-551

  Kittler, Ralf ^a,e   Zhou, Jie ^a   Hua, Sujun ^a,f   Ma, Lijia ^a   Liu, Yuwen ^a   Pendleton, Elisha ^a   Cheng, Chao ^b   Gerstein, Mark ^b,c   White, Kevin P ^a,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b YALE UNIVERSITY   (United States)

^c Yale University   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; CELL NUCLEUS RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; NUCLEAR RECEPTOR RELATED FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR GAMMA; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; X BOX BINDING PROTEIN 1; X BOX BINDING PROTEIN 1S;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CELL STRAIN MCF 7; CHROMATIN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BINDING SITES; BREAST NEOPLASMS; CHROMATIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MCF-7 CELLS; PPAR DELTA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; TRANSCRIPTION FACTORS;

EID: 84874232730     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.01.004     Document Type: Article

References (50)

1. Bernardo G.M., Lozada K.L., Miedler J.D., Harburg G., Hewitt S.C., Mosley J.D., Godwin A.K., Korach K.S., Visvader J.E., Kaestner K.H., et al. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development 2010, 137:2045-2054.
2. Camp R.L., Dolled-Filhart M., Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 2004, 10:7252-7259.
3. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
4. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33-43.
5. Carroll J.S., Meyer C.A., Song J., Li W., Geistlinger T.R., Eeckhoute J., Brodsky A.S., Keeton E.K., Fertuck K.C., Hall G.F., et al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 2006, 38:1289-1297.
6. Chang H.Y., Nuyten D.S.A., Sneddon J.B., Hastie T., Tibshirani R., Sørlie T., Dai H.Y., He Y.D.D., van't Veer L.J., Bartelink H., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 2005, 102:3738-3743.
7. Chen T. Nuclear receptor drug discovery. Curr. Opin. Chem. Biol. 2008, 12:418-426.
8. Conzen S.D. Minireview: nuclear receptors and breast cancer. Mol. Endocrinol. 2008, 22:2215-2228.
9. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:740-749.
10. Dunham I., Kundaje A., Aldred S.F., Collins P.J., Davis C.A., Doyle F., Epstein C.B., Frietze S., Harrow J., Kaul R., et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74. ENCODE Project Consortium.
11. Eeckhoute J., Keeton E.K., Lupien M., Krum S.A., Carroll J.S., Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res. 2007, 67:6477-6483.
12. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 2003, 3:859-868.
13. Evans R.M. The nuclear receptor superfamily: a rosetta stone for physiology. Mol. Endocrinol. 2005, 19:1429-1438.
14. Fullwood M.J., Liu M.H., Pan Y.F., Liu J., Xu H., Mohamed Y.B., Orlov Y.L., Velkov S., Ho A., Mei P.H., et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462:58-64.
15. Gerstein M.B., Lu Z.J., Van Nostrand E.L., Cheng C., Arshinoff B.I., Liu T., Yip K.Y., Robilotto R., Rechtsteiner A., Ikegami K., et al. Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science 2010, 330:1775-1787. modENCODE Consortium.
16. Gerstein M.B., Kundaje A., Hariharan M., Landt S.G., Yan K.K., Cheng C., Mu X.J., Khurana E., Rozowsky J., Alexander R., et al. Architecture of the human regulatory network derived from ENCODE data. Nature 2012, 489:91-100.
17. Giresi P.G., Kim J., McDaniell R.M., Iyer V.R., Lieb J.D. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res. 2007, 17:877-885.
18. Grivas P.D., Kiaris H., Papavassiliou A.G. Tackling transcription factors: challenges in antitumor therapy. Trends Mol. Med. 2011, 17:537-538.
19. Gronemeyer H., Gustafsson J.A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 2004, 3:950-964.
20. Hah N., Danko C.G., Core L., Waterfall J.J., Siepel A., Lis J.T., Kraus W.L. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 2011, 145:622-634.
21. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999, 17:1474-1481.
22. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
23. Hua S., Kallen C.B., Dhar R., Baquero M.T., Mason C.E., Russell B.A., Shah P.K., Liu J., Khramtsov A., Tretiakova M.S., et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol. Syst. Biol. 2008, 4:188.
24. Hua S., Kittler R., White K.P. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 2009, 137:1259-1271.
25. John S., Sabo P.J., Thurman R.E., Sung M.H., Biddie S.C., Johnson T.A., Hager G.L., Stamatoyannopoulos J.A. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 2011, 43:264-268.
26. Kong S.L., Li G., Loh S.L., Sung W.K., Liu E.T. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Mol. Syst. Biol. 2011, 7:526.
27. Kouros-Mehr H., Slorach E.M., Sternlicht M.D., Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006, 127:1041-1055.
28. Lefterova M.I., Zhang Y., Steger D.J., Schupp M., Schug J., Cristancho A., Feng D., Zhuo D., Stoeckert C.J., Liu X.S., Lazar M.A. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 2008, 22:2941-2952.
29. Lin C.Y., Vega V.B., Thomsen J.S., Zhang T., Kong S.L., Xie M., Chiu K.P., Lipovich L., Barnett D.H., Stossi F., et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet. 2007, 3:e87.
30. Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., Carroll J.S., Liu X.S., Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132:958-970.
31. Moorman C., Sun L.V., Wang J., de Wit E., Talhout W., Ward L.D., Greil F., Lu X.J., White K.P., Bussemaker H.J., van Steensel B. Hotspots of transcription factor colocalization in the genome of Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 2006, 103:12027-12032.
32. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009, 9:631-643.
33. Nègre N., Brown C.D., Ma L., Bristow C.A., Miller S.W., Wagner U., Kheradpour P., Eaton M.L., Loriaux P., Sealfon R., et al. A cis-regulatory map of the Drosophila genome. Nature 2011, 471:527-531.
34. Ni M., Chen Y., Lim E., Wimberly H., Bailey S.T., Imai Y., Rimm D.L., Liu X.S., Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011, 20:119-131.
35. Nielsen R., Pedersen T.A., Hagenbeek D., Moulos P., Siersbaek R., Megens E., Denissov S., Børgesen M., Francoijs K.J., Mandrup S., Stunnenberg H.G. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 2008, 22:2953-2967.
36. Poser I., Sarov M., Hutchins J.R., Hériché J.K., Toyoda Y., Pozniakovsky A., Weigl D., Nitzsche A., Hegemann B., Bird A.W., et al. BAC TransgeneOmics: a high-throughput method for exploration of protein function in mammals. Nat. Methods 2008, 5:409-415.
37. Reddy T.E., Pauli F., Sprouse R.O., Neff N.F., Newberry K.M., Garabedian M.J., Myers R.M. Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res. 2009, 19:2163-2171.
38. Roy S., Ernst J., Kharchenko P.V., Kheradpour P., Negre N., Eaton M.L., Landolin J.M., Bristow C.A., Ma L., Lin M.F., et al. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science 2010, 330:1787-1797. modENCODE Consortium.
39. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733.
40. Schug T.T., Berry D.C., Toshkov I.A., Cheng L., Nikitin A.Y., Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc. Natl. Acad. Sci. USA 2008, 105:7546-7551.
41. Siepel A., Bejerano G., Pedersen J.S., Hinrichs A.S., Hou M., Rosenbloom K., Clawson H., Spieth J., Hillier L.W., Richards S., et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005, 15:1034-1050.
42. Smoot M.E., Ono K., Ruscheinski J., Wang P.L., Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011, 27:431-432.
43. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. Article3.
44. Stephen R.L., Gustafsson M.C., Jarvis M., Tatoud R., Marshall B.R., Knight D., Ehrenborg E., Harris A.L., Wolf C.R., Palmer C.N. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res. 2004, 64:3162-3170.
45. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
46. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347:1999-2009.
47. Wang Q., Li W., Zhang Y., Yuan X., Xu K., Yu J., Chen Z., Beroukhim R., Wang H., Lupien M., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138:245-256.
48. Welboren W.J., van Driel M.A., Janssen-Megens E.M., van Heeringen S.J., Sweep F.C., Span P.N., Stunnenberg H.G. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J. 2009, 28:1418-1428.
49. Wilson B.J., Giguère V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol. Cancer 2008, 7:49.
50. Witt A.E., Hines L.M., Collins N.L., Hu Y.H., Gunawardane R.N., Moreira D., Raphael J., Jepson D., Koundinya M., Rolfs A., et al. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J. Proteome Res. 2006, 5:599-610.